Nurse Practitioner-Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial

Antoine Khati, Frederick L Altice, David Vlahov, William H Eger, Jessica Lee, Terry Bohonnon, Jeffrey A Wickersham, Francesca Maviglia, Nicholas Copenhaver, Roman Shrestha, Antoine Khati, Frederick L Altice, David Vlahov, William H Eger, Jessica Lee, Terry Bohonnon, Jeffrey A Wickersham, Francesca Maviglia, Nicholas Copenhaver, Roman Shrestha

Abstract

Background: The ongoing volatile opioid epidemic remains a significant public health concern, alongside continued outbreaks of HIV and hepatitis C virus among people who inject drugs. The limited access to and scale-up of medications for opioid use disorder (MOUD) among people who inject drugs, coupled with multilevel barriers to pre-exposure prophylaxis (PrEP) uptake, makes it imperative to integrate evidence-based risk reduction and HIV prevention strategies in innovative ways. To address this need, we developed an integrated rapid access to HIV prevention program for people who inject drugs (iRaPID) that incorporates same-day PrEP and MOUD for this population.

Objective: The primary objective of this pilot study is to assess the feasibility and acceptability of the program and evaluate its preliminary efficacy on PrEP and MOUD uptake for a future randomized controlled trial (RCT). We also aim to explore information on the implementation of the program in a real-world setting using a type I hybrid implementation trial design.

Methods: Using a type I hybrid implementation trial design, we are pilot testing the nurse practitioner-led iRaPID program while exploring information on its implementation in a real-world setting. Specifically, we will assess the feasibility and acceptability of the iRaPID program and evaluate its preliminary efficacy on PrEP and MOUD uptake in a pilot RCT. The enrolled 50 people who inject drugs will be randomized (1:1) to either iRaPID or treatment as usual (TAU). Behavioral assessments will occur at baseline, and at 1, 3, and 6 months. Additionally, we will conduct a process evaluation of the delivery and implementation of the iRaPID program to collect information for future implementation.

Results: Recruitment began in July 2021 and was completed in August 2022. Data collection is planned through February 2023. The Institutional Review Boards at Yale University and the University of Connecticut approved this study (2000028740).

Conclusions: This prospective pilot study will test a nurse practitioner-led, integrated HIV prevention program that incorporates same-day PrEP and MOUD for people who inject drugs. This low-threshold protocol delivers integrated prevention via one-stop shopping under the direction of nurse practitioners. iRaPID seeks to overcome barriers to delayed PrEP and MOUD initiation, which is crucial for people who inject drugs who have had minimal access to evidence-based prevention.

Trial registration: ClinicalTrials.gov NCT04531670; https://ichgcp.net/clinical-trials-registry/NCT04531670.

International registered report identifier (irrid): DERR1-10.2196/42585.

Keywords: HIV prevention; medications for opioid use disorder; opioid agonist therapy; opioid use disorder; people who inject drugs; pre-exposure prophylaxis; sexual risk.

Conflict of interest statement

Conflicts of Interest: FLA has grants from Gilead and Merck Pharmaceuticals and research consulting from Gilead Sciences. RS has research grants from Gilead Sciences. The authors have no further interests to declare.

©Antoine Khati, Frederick L Altice, David Vlahov, William H Eger, Jessica Lee, Terry Bohonnon, Jeffrey A Wickersham, Francesca Maviglia, Nicholas Copenhaver, Roman Shrestha. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 11.10.2022.

Figures

Figure 1
Figure 1
Integrated care process for same-day PrEP and MOUD compared to TAU. iRaPID: integrated rapid access to HIV prevention program for people who inject drugs; MOUD: medication for opioid use disorder; PrEP: pre-exposure prophylaxis; TAU: treatment as usual. *Patients interested in methadone prescriptions are referred to a methadone (or other appropriate) addiction treatment center.

References

    1. Des Jarlais Don C, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016 Mar 27;30(6):815–26. doi: 10.1097/QAD.0000000000001039.
    1. Mirzazadeh A, Evans J, Hahn J, Jain J, Briceno A, Shiboski S, Lum P, Bentsen C, Davis G, Shriver K, Dimapasoc M, Stone Mars, Busch Michael P, Page Kimberly. Continued transmission of HIV among young adults who inject drugs in San Francisco: still room for improvement. AIDS Behav. 2018 Apr;22(4):1383–1394. doi: 10.1007/s10461-017-1988-y. 10.1007/s10461-017-1988-y
    1. Schranz A, Barrett J, Hurt C, Malvestutto C, Miller W. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and Hepatitis C. Curr HIV/AIDS Rep. 2018 Jun;15(3):245–254. doi: 10.1007/s11904-018-0393-0. 10.1007/s11904-018-0393-0
    1. Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, Beyrer C. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021 Mar 20;397(10279):1139–1150. doi: 10.1016/S0140-6736(21)00391-3.S0140-6736(21)00391-3
    1. Green TC, McGowan SK, Yokell MA, Pouget ER, Rich JD. HIV infection and risk of overdose: a systematic review and meta-analysis. AIDS. 2012 Feb 20;26(4):403–17. doi: 10.1097/QAD.0b013e32834f19b6.
    1. HIV and injection drug use. Centers for Disease Control and Prevention. 2021. [2022-08-06]. .
    1. Injection drug use. Centers for Disease Control and Prevention. 2019. [2022-08-06].
    1. Arasteh K, Des Jarlais DC, Perlis TE. Alcohol and HIV sexual risk behaviors among injection drug users. Drug Alcohol Depend. 2008 May 1;95(1-2):54–61. doi: 10.1016/j.drugalcdep.2007.12.008. S0376-8716(07)00505-4
    1. Marshall BDL, Friedman SR, Monteiro JFG, Paczkowski M, Tempalski B, Pouget ER, Lurie MN, Galea S. Prevention and treatment produced large decreases in HIV incidence in a model of people who inject drugs. Health Aff (Millwood) 2014 Mar;33(3):401–9. doi: 10.1377/hlthaff.2013.0824. 33/3/401
    1. Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. AIDS Behav. 2008 May;12(3):335–53. doi: 10.1007/s10461-007-9313-9.
    1. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, Hankins CA. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010 Jul 24;376(9737):268–84. doi: 10.1016/S0140-6736(10)60743-X. S0140-6736(10)60743-X
    1. Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood) 2011 Aug;30(8):1411–9. doi: 10.1377/hlthaff.2011.0663. 30/8/1411
    1. Martin M, Vanichseni S, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Pitisuttithum P, Kaewkungwal J, van Griensven F, McNicholl JM, Tappero JW, Mastro TD, Kittimunkong S, Choopanya K. HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995-2012. EClinicalMedicine. 2019 Mar;9:44–51. doi: 10.1016/j.eclinm.2019.03.012. S2589-5370(19)30052-5
    1. Gangi MF, Karamouzian M, Nedjat S, Rahimi-Movaghar A, Yazdani K, Shokoohi M, Mirzazadeh A. HIV prevention cascades for injection and sexual risk behaviors among HIV-negative people who inject drug in Iran. Int J Drug Policy. 2020 Oct;84:102868. doi: 10.1016/j.drugpo.2020.102868. S0955-3959(20)30208-5
    1. Bhatia R, Modali L, Lowther M, Glick N, Bell M, Rowan S, Keglovitz K, Schneider J . Outcomes of preexposure prophylaxis referrals from public STI clinics and implications for the preexposure prophylaxis continuum. Sex Transm Dis. 2018 Jan;45(1):50–55. doi: 10.1097/OLQ.0000000000000690.
    1. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004145. doi: 10.1002/14651858.CD004145.pub4.
    1. Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic revie. Evid Based Med Public Health. 2016;2:e1129.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4.
    1. Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. J Acquir Immune Defic Syndr. 2018 Nov 01;79(3):288–295. doi: 10.1097/QAI.0000000000001827. 00126334-201811010-00002
    1. Mukandavire C, Low A, Mburu G, Trickey A, May MT, Davies CF, French CE, Looker KJ, Rhodes T, Platt L, Guise A, Hickman M, Vickerman P. Impact of opioid substitution therapy on the HIV prevention benefit of antiretroviral therapy for people who inject drugs. AIDS. 2017 May 15;31(8):1181–1190. doi: 10.1097/QAD.0000000000001458.
    1. Nosyk B, Min JE, Evans E, Li L, Liu L, Lima VD, Wood E, Montaner JSG. The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality Among HIV-Positive People Who Inject Drugs. Clin Infect Dis. 2015 Oct 01;61(7):1157–65. doi: 10.1093/cid/civ476. civ476
    1. Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, Millar T. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016 Feb;111(2):298–308. doi: 10.1111/add.13193.
    1. Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health. 2013 May;103(5):917–22. doi: 10.2105/AJPH.2012.301049.
    1. Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, Grebely J, Dumchev KV, Griffiths P, Hines L, Cunningham EB, Mattick RP, Lynskey M, Marsden J, Strang J, Degenhardt L. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. The Lancet Global Health. 2017 Dec;5(12):e1208–e1220. doi: 10.1016/s2214-109x(17)30373-x.
    1. Priest KC, Gorfinkel L, Klimas J, Jones AA, Fairbairn N, McCarty D. Comparing Canadian and United States opioid agonist therapy policies. Int J Drug Policy. 2019 Dec;74:257–265. doi: 10.1016/j.drugpo.2019.01.020. S0955-3959(19)30028-3
    1. Medicaid coverage of medication-assisted treatment for alcohol and opioid use disorders and of medication for the reversal of opioid overdose. Substance Abuse and Mental Health Services Administration. 2018. [2022-08-09]. .
    1. The Foundation for AIDS Research. Toward an effective strategy to combat HIV. Hepatitis C and the opioid epidemic: recommendations for policy makers. [2022-08-07]. .
    1. Alpren C, Dawson E, John B, Cranston K, Panneer N, Fukuda H, Roosevelt K, Klevens R, Bryant J, Peters P, Lyss S, Switzer Wm, Burrage A, Murray A, Agnew-Brune C, Stiles T, McClung P, Campbell Em, Breen C, Randall Lm, Dasgupta S, Onofrey S, Bixler D, Hampton K, Jaeger Jl, Hsu Kk, Adih W, Callis B, Goldman Lr, Danner Sp, Jia H, Tumpney M, Board A, Brown C, DeMaria A, Buchacz K. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs-Massachusetts, 2015-2018. Am J Public Health. 2020 Jan;110(1):37–44. doi: 10.2105/AJPH.2019.305366.
    1. Conrad C. Morbidity and mortality weekly report: outbreak of HIV infection linked to injection drug use of oxymorphone. Centers for Disease Control and Prevention. [2022-08-06]. .
    1. Gonsalves GS, Crawford FW. Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study. Lancet HIV. 2018 Oct;5(10):e569–e577. doi: 10.1016/S2352-3018(18)30176-0. S2352-3018(18)30176-0
    1. Low AJ, Mburu G, Welton NJ, May MT, Davies CF, French C, Turner KM, Looker KJ, Christensen H, McLean S, Rhodes T, Platt L, Hickman M, Guise A, Vickerman P. Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2016 Oct 15;63(8):1094–1104. doi: 10.1093/cid/ciw416. ciw416
    1. Preexposure prophylaxis for the prevention of HIV infection in the United States. Centers for Disease Control and Prevention. 2017. [2022-08-07]. .
    1. Alpren C, Dawson EL, John B, Cranston K, Panneer N, Fukuda HD, Roosevelt K, Klevens RM, Bryant J, Peters PJ, Lyss SB, Switzer WM, Burrage A, Murray A, Agnew-Brune C, Stiles T, McClung P, Campbell EM, Breen C, Randall LM, Dasgupta S, Onofrey S, Bixler D, Hampton K, Jaeger JL, Hsu KK, Adih W, Callis B, Goldman LR, Danner SP, Jia H, Tumpney M, Board A, Brown C, DeMaria A, Buchacz K. Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs-Massachusetts, 2015-2018. Am J Public Health. 2020 Jan;110(1):37–44. doi: 10.2105/AJPH.2019.305366.
    1. Bhatia R, Modali L, Lowther M, Glick N, Bell M, Rowan S, Keglovitz K, Schneider J. Outcomes of preexposure prophylaxis referrals from public STI clinics and implications for the preexposure prophylaxis continuum. Sex Transm Dis. 2018 Jan;45(1):50–55. doi: 10.1097/OLQ.0000000000000690.
    1. Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy. 2015 Jan 8;10(1):1. doi: 10.1186/1747-597x-10-1.
    1. Shrestha R, Alias H, Wong LP, Altice FL, Lim SH. Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: results from a conjoint-based analysis. BMC Public Health. 2020 Nov 25;20(1):1777. doi: 10.1186/s12889-020-09832-w. doi: 10.1186/s12889-020-09832-w.
    1. Mistler CB, Curley CM, Rosen AO, El-Krab R, Wickersham JA, Copenhaver MM, Khati A, Shrestha R. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals. J Community Health. 2021 Oct;46(5):960–966. doi: 10.1007/s10900-021-00979-0. 10.1007/s10900-021-00979-0
    1. Substance AbuseMental Health Services Administration. Medications for Opioid Use Disorder for Healthcare and Addiction Professionals, Policymakers, Patients, and Families. Treatment Improved Protocol TIP 63. [2022-08-06]. .
    1. Nelson LE, McMahon JM, Leblanc NM, Braksmajer A, Crean HF, Smith K, Xue Y. Advancing the case for nurse practitioner-based models to accelerate scale-up of HIV pre-exposure prophylaxis. J Clin Nurs. 2019 Jan;28(1-2):351–361. doi: 10.1111/jocn.14675.
    1. Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP Awareness, Familiarity, Comfort, and Prescribing Experience among US Primary Care Providers and HIV Specialists. AIDS Behav. 2017 May;21(5):1256–1267. doi: 10.1007/s10461-016-1625-1.10.1007/s10461-016-1625-1
    1. Spetz J, Toretsky C, Chapman S, Phoenix B, Tierney M. Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions. JAMA. 2019 Apr 09;321(14):1407–1408. doi: 10.1001/jama.2019.0834. 2730102
    1. Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, Tetrault JM, Shah M, Fiellin DA, Blackstock O. Primary Care Physicians' Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. AIDS Behav. 2017 Apr;21(4):1025–1033. doi: 10.1007/s10461-016-1612-6. 10.1007/s10461-016-1612-6
    1. Ferro EG, Culbert GJ, Wickersham JA, Marcus R, Steffen AD, Pauls HA, Westergaard RP, Lee CK, Kamarulzaman A, Altice FL. Physician Decisions to Defer Antiretroviral Therapy in Key Populations: Implications for Reducing Human Immunodeficiency Virus Incidence and Mortality in Malaysia. Open Forum Infect Dis. 2017;4(1):ofw219. doi: 10.1093/ofid/ofw219. ofw219
    1. Shrestha R, Altice FL, Karki P, Copenhaver MM. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study. AIDS Behav. 2018 Aug;22(8):2640–2649. doi: 10.1007/s10461-018-2099-0. 10.1007/s10461-018-2099-0
    1. Westergaard RP, Ambrose BK, Mehta SH, Kirk GD. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc. 2012 Feb 23;15(1):10. doi: 10.1186/1758-2652-15-10. 1758-2652-15-10
    1. Kamis KF, Marx GE, Scott KA, Gardner EM, Wendel KA, Scott ML, Montgomery AE, Rowan SE. Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care. Open Forum Infect Dis. 2019 Jul;6(7):ofz310. doi: 10.1093/ofid/ofz310. ofz310
    1. Khosropour CM, Backus KV, Means AR, Beauchamps L, Johnson K, Golden MR, Mena L. A Pharmacist-Led, Same-Day, HIV Pre-Exposure Prophylaxis Initiation Program to Increase PrEP Uptake and Decrease Time to PrEP Initiation. AIDS Patient Care STDS. 2020 Jan;34(1):1–6. doi: 10.1089/apc.2019.0235.
    1. Kamis KF, Marx GE, Scott KA, Gardner EM, Wendel KA, Scott ML, Montgomery AE, Rowan SE. Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care. Open Forum Infect Dis. 2019 Jul;6(7):ofz310. doi: 10.1093/ofid/ofz310. ofz310
    1. Rowan SE, Patel RR, Schneider JA, Smith DK. Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. Lancet HIV. 2021 Feb;8(2):e114–e120. doi: 10.1016/S2352-3018(20)30256-3.S2352-3018(20)30256-3
    1. Herrick AL, Lim SH, Plankey MW, Chmiel JS, Guadamuz TE, Guadamuz TT, Kao U, Shoptaw S, Carrico A, Ostrow D, Stall R. Adversity and syndemic production among men participating in the multicenter AIDS cohort study: a life-course approach. Am J Public Health. 2013 Jan;103(1):79–85. doi: 10.2105/AJPH.2012.300810.
    1. Task shifting: global recommendations and guidelines. World Health Organization. 2008. [2022-08-15]. .
    1. Schmidt HA, Schaefer R, Nguyen VTT, Radebe M, Sued O, Rodolph M, Ford N, Baggaley R. Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job? Lancet HIV. 2022 May;9(5):e363–e366. doi: 10.1016/S2352-3018(22)00006-6. S2352-3018(22)00006-6
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217–26. doi: 10.1097/MLR.0b013e3182408812.
    1. Davila K. Overdose data to action: trends in substance use, overdose, and treatment in the Quinnipiack valley health district and new haven. ctdatahaven. 2021. [2022-08-15]. .
    1. HIV infection cases by year of first diagnosis, sex, race, and risk, New Haven County, 2011 - 2020. Connecticut DOPH. 2021. [2022-08-15]. .
    1. Gibson BA, Ghosh D, Morano JP, Altice FL. Accessibility and utilization patterns of a mobile medical clinic among vulnerable populations. Health Place. 2014 Jul;28:153–66. doi: 10.1016/j.healthplace.2014.04.008. S1353-8292(14)00066-5
    1. Gibson BA, Morano JP, Walton MR, Marcus R, Zelenev A, Bruce RD, Altice FL. Innovative Program Delivery and Determinants of Frequent Visitation to a Mobile Medical Clinic in an Urban Setting. J Health Care Poor Underserved. 2017;28(2):643–662. doi: 10.1353/hpu.2017.0065.S1548686917200205
    1. Morano JP, Gibson BA, Altice FL. The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS One. 2013;8(5):e64321. doi: 10.1371/journal.pone.0064321. PONE-D-12-39320
    1. Morano JP, Zelenev A, Lombard A, Marcus R, Gibson BA, Altice FL. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health. 2014 Oct;39(5):922–34. doi: 10.1007/s10900-014-9932-9.
    1. Morano JP, Zelenev A, Walton MR, Bruce RD, Altice FL. Latent tuberculosis infection screening in foreign-born populations: a successful mobile clinic outreach model. Am J Public Health. 2014 Aug;104(8):1508–15. doi: 10.2105/AJPH.2014.301897.
    1. Bryant-Lukosius D, Dicenso A. A framework for the introduction and evaluation of advanced practice nursing roles. J Adv Nurs. 2004 Dec;48(5):530–40. doi: 10.1111/j.1365-2648.2004.03235.x.JAN3235
    1. Preexposure prophylaxis for the prevention of HIV infection in the United States. Centers for Disease Control and Prevention. 2021. [2022-08-16]. .
    1. Center for Substance Abuse Treatment . Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2016.
    1. Conway DP, Holt M, Couldwell DL, Smith DE, Davies SC, McNulty A, Keen P, Cunningham P, Guy R, Sydney Rapid HIV Test Study Barriers to HIV testing and characteristics associated with never testing among gay and bisexual men attending sexual health clinics in Sydney. J Int AIDS Soc. 2015;18:20221. doi: 10.7448/IAS.18.1.20221. 20221
    1. O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, Ryan M. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022 May 11;12(5):e048478. doi: 10.1136/bmjopen-2020-048478. bmjopen-2020-048478
    1. Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, Stoltey JE, Volk JE. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540–546. doi: 10.1097/QAI.0000000000001129. 00126334-201612150-00007
    1. Riddell J, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261–1268. doi: 10.1001/jama.2018.1917.2676116
    1. Sanchez Conde M, Vivancos Gallego MJ, Moreno Guillen S. Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties. Farm Hosp. 2017 Sep 01;41(5):630–637. doi: 10.7399/fh.10821. doi: 10.7399/fh.10821.
    1. Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic. Int J Drug Policy. 2017 Oct;48:44–53. doi: 10.1016/j.drugpo.2017.05.014. S0955-3959(17)30118-4
    1. Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. Int J Drug Policy. 2017 Sep;47:187–195. doi: 10.1016/j.drugpo.2017.07.023. S0955-3959(17)30237-2
    1. Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019 May;100:18–28. doi: 10.1016/j.jsat.2019.01.019. S0740-5472(18)30422-7
    1. Shrestha R, Altice F, Karki P, Copenhaver M. Developing an Integrated, Brief Biobehavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: The Process and Outcome of Formative Research. Front Immunol. 2017;8:561. doi: 10.3389/fimmu.2017.00561. doi: 10.3389/fimmu.2017.00561.
    1. Tarnowski KJ, Simonian SJ. Assessing treatment acceptance: the Abbreviated Acceptability Rating Profile. J Behav Ther Exp Psychiatry. 1992 Jun;23(2):101–6. doi: 10.1016/0005-7916(92)90007-6.0005-7916(92)90007-6
    1. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5(2):74–9. doi: 10.1310/JFXH-G3X2-EYM6-D6UG.
    1. Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother. 2016 Nov;60(11):6692–6697. doi: 10.1128/AAC.01017-16. AAC.01017-16
    1. Castillo-Mancilla JR, Zheng J, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb;29(2):384–90. doi: 10.1089/AID.2012.0089.
    1. Zheng J, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016 Apr 15;122:16–20. doi: 10.1016/j.jpba.2016.01.038. S0731-7085(16)30038-3
    1. Palmgren J, Diggle PJ, Heagarty P, Liang KY, Zeger SL. Analysis of longitudinal data (2nd ed.) Statist. Med. 2004 Nov 15;23(21):3399–3401. doi: 10.1002/sim.1701. doi: 10.1002/sim.1701.
    1. Muller KE, Lavange LM, Ramey SL, Ramey CT. Power Calculations for General Linear Multivariate Models Including Repeated Measures Applications. J Am Stat Assoc. 1992 Dec 01;87(420):1209–1226. doi: 10.1080/01621459.1992.10476281.
    1. Edwards L. Applied Analysis of Variance in Behavioral Science. New York: M. Dekker; 1993.
    1. State Practice Environment. American Association of Nurse Practitioners. 2022. [2022-06-25]. .
    1. Vanhamel J, Rotsaert A, Reyniers T, Nöstlinger C, Laga M, Van Landeghem E, Vuylsteke B. The current landscape of pre-exposure prophylaxis service delivery models for HIV prevention: a scoping review. BMC Health Serv Res. 2020 Jul 31;20(1):704. doi: 10.1186/s12913-020-05568-w. 10.1186/s12913-020-05568-w
    1. Mark TL, Treiman K, Padwa H, Henretty K, Tzeng J, Gilbert M. Addiction Treatment and Telehealth: Review of Efficacy and Provider Insights During the COVID-19 Pandemic. Psychiatr Serv. 2022 May;73(5):484–491. doi: 10.1176/appi.ps.202100088.
    1. Allen ST, O'Rourke A, White RH, Smith KC, Weir B, Lucas GM, Sherman SG, Grieb SM. Barriers and facilitators to PrEP use among people who inject drugs in rural Appalachia: A Qualitative Study. AIDS Behav. 2020 Jun;24(6):1942–1950. doi: 10.1007/s10461-019-02767-3. 10.1007/s10461-019-02767-3
    1. Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handanagic S, Jones CM, McClung RP, Asher AK. Syringe Services Programs' Role in Ending the HIV Epidemic in the U.S.: Why We Cannot Do It Without Them. Am J Prev Med. 2021 Nov;61(5 Suppl 1):S118–S129. doi: 10.1016/j.amepre.2021.05.044. S0749-3797(21)00389-5
    1. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010 Jul 24;376(9737):285–301. doi: 10.1016/S0140-6736(10)60742-8.S0140-6736(10)60742-8
    1. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 Aug 12;385(7):595–608. doi: 10.1056/NEJMoa2101016.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj